thymodepressin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

thymodepressin: a synthetic peptide, promoted take of transplanted hemopoietic precursor cells in the bone marrow of irradiated mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	7275810
CHEMBL ID	3137306
SCHEMBL ID	733964
MeSH ID	M0417847

Synonyms (28)

Synonym
thymodepressin
ccris 9010
270250-97-0
orilotimod [usan:inn]
unii-q66z43c5xm
orilotimod
186087-26-3
d-tryptophan, d-gamma-glutamyl-
d-gamma-glutamyl-d-tryptophan
q66z43c5xm ,
(2r)-2-amino-5-(((1r)-1-carboxy-2-(1h-indol-3-yl)ethyl)amino)-5-oxopentanoic acid
gamma-d-glu-d-trp
apo-805
timodepressin
apo805
CHEMBL3137306
orilotimod [inn]
d-tryptophan, d-.gamma.-glutamyl-
thymodepressin [who-dd]
d-.gamma.-glutamyl-d-tryptophan
orilotimod [usan]
SCHEMBL733964
D10651
orilotimod (usan/inn)
DTXSID10181511
CATMPQFFVNKDEY-DGCLKSJQSA-N
Q27287050
(2r)-2-amino-5-[[(1r)-1-carboxy-2-(1h-indol-3-yl)ethyl]amino]-5-oxopentanoic acid

Research Excerpts

Overview

Thymodepressin is a new synthetic hemoregulatory dipeptide.

Excerpt	Reference	Relevance
"Thymodepressin is a new synthetic hemoregulatory dipeptide (gamma-D-Glu-D-Trp). "	( [Use of thymodepressin for treating autoimmune cytopenia]. Deĭgin, VI; Orlova, NV; Pavlov, VV; Saenko, AS; Selivanova, EI; Smirnova, SG; Vinogradova, IuE; Zamulaeva, IA, 2002)	2.19

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (66.67)	29.6817
2010's	1 (11.11)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2	1	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
2,5-dioxopiperazine piperazine-2,5-dione : A cyclic peptide that is piperazine in which the hydrogens at positions 2 and 5 are replaced by oxo groups.	2.25	1	2,5-diketopiperazines; cyclic peptide
6-methyluracil 6-methyluracil: RN given refers to unlabeled cpd; structure. 6-methyluracil : A pyrimidone that is uracil with a methyl group at position 6.	2	1	pyrimidone	metabolite
alpha-glutamyltryptophan alpha-glutamyltryptophan: RN refers to L-isomer; a naturally occurring thymic immunomodulator. Glu-Trp : A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage.	2.25	1	dipeptide	angiogenesis modulating agent; antineoplastic agent; immunomodulator; metabolite

Condition	Relationship Strength	Studies
Graft-Versus-Host Disease [description not available]	2.31	1
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	2.31	1
Benign Neoplasms [description not available]	2.04	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.04	1
Eczema, Atopic [description not available]	2.44	2
Lichen Ruber Planus [description not available]	2.06	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	2.44	2
Lichen Planus An inflammatory, pruritic disease of the skin and mucous membranes, which can be either generalized or localized. It is characterized by distinctive purplish, flat-topped papules having a predilection for the trunk and flexor surfaces. The lesions may be discrete or coalesce to form plaques. Histologically, there is a saw-tooth pattern of epidermal hyperplasia and vacuolar alteration of the basal layer of the epidermis along with an intense upper dermal inflammatory infiltrate composed predominantly of T-cells. Etiology is unknown.	2.06	1
Anemia, Hemolytic, Acquired [description not available]	2.01	1
Autoimmune Thrombocytopenia [description not available]	2.01	1
Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).	2.01	1
Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.	2.01	1

chemdatabank.com